CLINICAL TRIALS PROFILE FOR AMINOLEVULINIC ACID HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for AMINOLEVULINIC ACID HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00002963 ↗ | Photodynamic Therapy in Treating Patients With Skin Cancer | Completed | Roswell Park Cancer Institute | Phase 2 | 1993-11-01 | RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid cream may be effective in treating patients with skin cancer. PURPOSE: This randomized phase II trial is studying how well photodynamic therapy works in treating patients with skin cancer. |
| NCT00002975 ↗ | Photodynamic Therapy in Treating Patients With Skin Cancer | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-02-01 | RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid may be effective in treating patients with skin cancer. PURPOSE: This randomized phase II trial is studying how well photodynamic therapy that includes aminolevulinic acid works in treating patients with skin cancer. |
| NCT00002975 ↗ | Photodynamic Therapy in Treating Patients With Skin Cancer | Completed | Roswell Park Cancer Institute | Phase 2 | 1997-02-01 | RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. Photodynamic therapy using aminolevulinic acid may be effective in treating patients with skin cancer. PURPOSE: This randomized phase II trial is studying how well photodynamic therapy that includes aminolevulinic acid works in treating patients with skin cancer. |
| NCT00054171 ↗ | Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-02-01 | RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs such as aminolevulinic acid are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of photodynamic therapy using aminolevulinic acid in treating patients who have cutaneous T-cell lymphoma, B-cell lymphoma, or early chronic lymphocytic leukemia involving the skin. |
| NCT00054171 ↗ | Photodynamic Therapy in Treating Patients With Lymphoma or Chronic Lymphocytic Leukemia | Completed | Roswell Park Cancer Institute | Phase 2 | 1999-02-01 | RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill cancer cells. Photosensitizing drugs such as aminolevulinic acid are absorbed by cancer cells and, when exposed to light, become active and kill the cancer cells. PURPOSE: Randomized phase II trial to study the effectiveness of photodynamic therapy using aminolevulinic acid in treating patients who have cutaneous T-cell lymphoma, B-cell lymphoma, or early chronic lymphocytic leukemia involving the skin. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMINOLEVULINIC ACID HYDROCHLORIDE
Condition Name
Clinical Trial Locations for AMINOLEVULINIC ACID HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for AMINOLEVULINIC ACID HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for AMINOLEVULINIC ACID HYDROCHLORIDE
Sponsor Name
